WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 9 fonti

AbbVie's Big Immunology Acquisition

In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more.

Raccontata dabiopharmadive.comendpoints.newsstatnews.comwiwo.debenzinga.cominvestors.comexpansion.commilanofinanza.itforbes.com

Confronto fonti

6 prospettive sulla stessa storia
AI · summaries
forbes.comStai leggendo23 h fa

AbbVie's Big Immunology Acquisition

In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more.

originale

Timeline cronologica

  1. lunedì 22 giugno 2026·biopharmadive.com

    AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

    AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster”…

  2. lunedì 22 giugno 2026·endpoints.news

    AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

    AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.

biopharmadive.com
2 g fa

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sales potential.

Leggi questa versione → originale
benzinga.com1 g fa

AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic

AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.

Leggi questa versione → originale
statnews.com2 g fa

AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie acquires Apogee for $10.9B to add zumilokibart, an immunology drug dosed 2–4 times yearly for inflammatory diseases. The deal signals pharma's trend toward consolidation via focused biotech acquisitions—key signal for partnership and M&A strategy.

Leggi questa versione → originale
investors.com2 g fa

AbbVie Goes On The Offensive With $10.9 Billion Takeover

The deal bolsters AbbVie's immunology and inflammation pipeline, answering a key investor question about what comes after Skyrizi.

Leggi questa versione → originale
endpoints.news2 g fa

AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.

Leggi questa versione → originale
  • lunedì 22 giugno 2026·statnews.com

    AbbVie to buy Apogee Therapeutics in nearly $11B deal

    AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.

  • lunedì 22 giugno 2026·wiwo.de

    Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar

    AbbVie stärkt mit der Übernahme von Apogee Therapeutics sein Immunologie-Portfolio und setzt auf neue Wachstumstreiber.

  • lunedì 22 giugno 2026·benzinga.com

    AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther

    AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.

  • lunedì 22 giugno 2026·investors.com

    AbbVie Goes On The Offensive With $10.9 Billion Takeover

    The deal bolsters AbbVie's immunology and inflammation pipeline, answering a key investor question about what comes after Skyrizi.

  • lunedì 22 giugno 2026·statnews.com

    Another big deal, another sign biotech M&A is back

    AbbVie buys Apogee Therapeutics, LSD therapy Phase 3 results, and more biotech news from The Readout

  • lunedì 22 giugno 2026·expansion.com

    AbbVie compra la 'biotech' Apogee por 10.900 millones de d�lares

    Seg�n los t�rminos del acuerdo, AbbVie pagar� un prima cercana al 50% respecto al cierre en Bolsa de Apogee Therapeutics el pasado jueves, ya que el viernes no hubo sesi�n en...

  • martedì 23 giugno 2026·milanofinanza.it

    AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News

    <p>AbbVie ha raggiunto un accordo per l'acquisizione di Apogee Therapeutics per circa 10,9 miliardi di dollari in contanti, un'operazione che rafforza il portafoglio di farmaci…

  • martedì 23 giugno 2026·benzinga.com

    AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic

    AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.

  • mercoledì 24 giugno 2026·forbes.com

    AbbVie's Big Immunology Acquisition

    In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade…